GW Pharmaceuticals Plc - Strategic SWOT Analysis Review

GW Pharmaceuticals Plc - Strategic SWOT Analysis Review

- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

GW Pharmaceuticals Plc (GW Pharmaceuticals), a subsidiary of Jazz Pharmaceuticals, is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary plant-derived cannabinoid product platform. The company offers Sativex for the treatment of spasticity due to multiple sclerosis and Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also advancing its pipeline for the treatment of Rett syndrome, spasticity associated with spinal cord injury, post-traumatic stress disorder, schizophrenia, epilepsy, and neonatal hypoxic-ischemic encephalopathy. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridge, the UK.

GW Pharmaceuticals Plc Key Recent Developments

Apr 28,2021: GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation
Feb 23,2021: Jazz Pharmaceuticals to Acquire GW Pharmaceuticals
Feb 16,2021: GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress
Jan 11,2021: GW Pharmaceuticals provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note:Some sections may be missing if data is unavailable for the company.